Wells Fargo & Company Kura Oncology, Inc. Transaction History
Wells Fargo & Company
- $433 Billion
- Q4 2024
A detailed history of Wells Fargo & Company transactions in Kura Oncology, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 34,989 shares of KURA stock, worth $289,708. This represents 0.0% of its overall portfolio holdings.
Number of Shares
34,989
Previous 23,562
48.5%
Holding current value
$289,708
Previous $460,000
33.91%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding KURA
# of Institutions
196Shares Held
79.6MCall Options Held
98.7KPut Options Held
70.1K-
Black Rock Inc. New York, NY6.97MShares$57.7 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.8MShares$48 Million0.71% of portfolio
-
Suvretta Capital Management, LLC New York, NY5.08MShares$42 Million1.84% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.82MShares$39.9 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA4.45MShares$36.9 Million0.63% of portfolio
About Kura Oncology, Inc.
- Ticker KURA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 66,893,000
- Market Cap $554M
- Description
- Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...